Concepedia

Michelle Casey

MC

Statistics

Publications

39

Citations

10.5K

H-Index

28

Active since

2004

Affiliations

GlaxoSmithKline (United States)(Current)

Pfizer (United States)

Institut Gustave Roussy

Charité - Universitätsmedizin Berlin

Pfizer (Italy)

Michelle Casey is an author at GlaxoSmithKline (United States) specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2004–2024

39

Publications

39

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +17

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

, , +14

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

, , +15

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Kimberly Blackwell, Harold J. Burstein, Anna Maria Storniolo et al. · Journal of Clinical Oncology · 2010 · 960 citations · Full text

, , +17

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

David Cameron, Michelle Casey, Michael F. Press et al. · Breast Cancer Research and Treatment · 2008 · 803 citations

, , +17

1–5 of 39